Peripheral Vascular Disease Grows at Double-Digit Rates, Waits for Solutions

New technologies are wanted for peripheral artery disease, which affects 12 to 14 million people in the US, two to three million of them serious enough to warrant intervention, according to "US Markets for Interventional Peripheral Vascular Disease Management Products and Technologies," a report recently issued by Windhover-Elsevier. In addition to peripheral arterial disease, approximately eight million people in the US suffer from chronic venous insufficiency, of whom more than three million develop venous ulcers. Aortic aneurysms affect another two million people in the US, and the prevalence is increasing due to the increasing number of the elderly. But one of the largest serious problems in peripheral vascular disease that has few solutions is deep vein thrombosis (DVT). In the US approximately 25 million suffer from this condition and two million more are diagnosed each year. DVT brings the danger of pulmonary embolism and death. These and other categories in peripheral vascular disease are forecast to grow by double-digit rates, including mechanical atherectomy systems, chronic total occlusion crossing systems, and endovascular cryotherapy systems.

As far as medical markets are concerned, peripheral artery disease is still the baby sister of cardiovascular disease, walking in its shadow and making use of its hand-me-downs. Yes, just like coronary disease, peripheral artery disease is a function of atherosclerosis and lumen narrowing and blockage, and they share the same cardiovascular risk factors, like smoking, diabetes, obesity, high blood pressure, and 65 and older patient population. But it's a different disease with its own anatomical and biomechanical challenges, and since it's also deadly, deserves its own therapies.

Percutaneous transluminal angioplasty (PTA), borrowed from coronary markets, still remains the dominant treatment according to "US Markets for Interventional Peripheral Vascular Disease Management Products and Technologies," (a report recently published by the Medtech Insight division of Elsevier), and is still sometimes accompanied by the off-label use of stents adapted from coronary and biliary applications. Progress is being made on the part of companies developing peripherally dedicated stents. WL Gore & Associates Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By 

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.